Last reviewed · How we verify
Disorder of skin
Approved treatments
- Cortone
- Decadron · Generic (originally Merck)
- prednison · Wen Zhang
- Medrol · Generic (originally Upjohn/Pfizer)
Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions. - Infuvite Adult · Pfizer
- Rodinolone
- Deltasone · Generic (originally Schering)
- Betametasone
Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system. - Bepanthen · RWTH Aachen University
- Prelone · Generic (originally Schering)
- prednisolon · Hannover Medical School
- Methylprednisolon · Leiden University Medical Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Disorder of skin patent landscape — cliff calendar, originator estates, attackable patents
- Disorder of skin treatment landscape brief
- Disorder of skin treatment updates RSS
Frequently asked questions about Disorder of skin
What drugs treat Disorder of skin?
Tracked treatments include Cortone, Decadron, prednison, Medrol, Infuvite Adult, Rodinolone, Deltasone, Betametasone.
What is the treatment for Disorder of skin?
Standard treatment for Disorder of skin includes Cortone, Decadron, prednison, Medrol, Infuvite Adult. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Disorder of skin patent cliff · Disorder of skin CI report
- Treatment: Cortone
- Treatment: Decadron · Generic (originally Merck)
- Treatment: prednison · Wen Zhang
- Treatment: Medrol · Generic (originally Upjohn/Pfizer)
- Treatment: Infuvite Adult · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing